Cell-Penetrating CD40 Blocking Peptides Without Thrombosis Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapies targeting the CD40-CD154 pathway for treating CD40-mediated diseases, such as inflammatory diseases, are hindered by the risk of platelet aggregation and thrombosis, and indiscriminate inhibition can compromise host resistance to infections.
Innovation Solution
Administering cell-penetrating peptides that selectively inhibit the binding of TRAF2/3 or TRAF6 to CD40, thereby blocking pro-inflammatory responses without affecting CD40 ligand binding, thus reducing inflammation while preserving immune function and avoiding thrombosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-CD154 monoclonal antibodies are administered to block CD40-CD154 pathway, then inflammatory diseases are controlled, but platelet aggregation and thrombosis occur
Solution Approach 1:
The patent extracts and targets only the specific CD40-TRAF2/3 signaling pathway using cell-penetrating peptides that block TRAF2/3 binding to CD40, while leaving the CD40-CD154 interaction intact. This selective extraction of the harmful signaling pathway eliminates platelet aggregation and thrombosis side effects while maintaining disease control efficacy.
Solution Approach 2:
The patent introduces cell-penetrating peptides as intermediary molecules that specifically interfere with the CD40-TRAF2/3 interaction. These peptides act as mediators that block the pro-inflammatory signaling pathway without preventing the natural CD40-CD154 binding, thereby resolving the contradiction between disease control and thrombosis prevention.
2Object-generated harmful factors
If CD40 pathway is indiscriminately inhibited, then inflammatory responses are reduced, but host resistance to infections is compromised
Solution Approach 1:
The patent applies local quality by specifically targeting the CD40-TRAF2/3 signaling pathway within the CD40 system, rather than globally inhibiting all CD40 functions. The cell-penetrating peptides selectively block the pro-inflammatory TRAF2/3 pathway while preserving other CD40-mediated immune functions, including host resistance to infections.
Solution Approach 2:
The patent segments the CD40 signaling pathways by selectively interfering with only the CD40-TRAF2/3 interaction. This segmentation allows the pro-inflammatory pathway to be blocked while other parallel signaling pathways remain functional, maintaining host resistance without excessive inflammation.
3Object-generated harmful factors
If CD40-TRAF2/3 pathway is selectively blocked, then pro-inflammatory responses are inhibited, but CD40 ligand binding function is preserved
Solution Approach 1:
The patent extracts and selectively blocks only the CD40-TRAF2/3 signaling component using cell-penetrating peptides, while leaving the CD40-CD154 binding function intact. This selective extraction achieves anti-inflammatory effects without compromising immune function.
Data Source
AI summary
A cell-penetrating peptide includes a membrane transduction domain linked to a CD40-TRAF2,3 blocking peptide that includes an amino acid sequence substantially identical to the amino acid sequence of the TRAF2,3 binding domain to CD40 or a retro-inverso amino acid sequence thereof.